Spyre Therapeutics stock reacts to new SPY772 program and SKYLIGHT trial launch

Spyre Therapeutics (SYRE) is in focus after the company launched its SPY772 combination program and began SKYLIGHT, a Phase 2 proof of concept trial in Hidradenitis Suppurativa.

Both efforts target dual inhibition of TL1A and IL-17A/F in moderate to severe HS. The approach uses SPY072 alongside background bimekizumab therapy for around 150 adult participants.

Spyre Therapeutics’ latest SKYLIGHT trial update lands after a period of strong momentum, with a 30 day share price return of 11.91% and a year to date share price return of 256.18%, while the 1 year total shareholder return is very large.

If this kind of clinical progress has your attention, it could be a good time to broaden your watchlist with 42 healthcare AI stocks

Spyre Therapeutics now trades at US$108.92, while the average analyst target sits near US$124.71. After such a sharp move, where does a reasonable view of fair value fall within that range of estimates?

Preferred Price-to-Book Multiple of 10.1x for Spyre Therapeutics: Is it justified?

Spyre Therapeutics now trades on a P/B ratio of 10.1x, which sits close to the peer average of 10.6x but far above the broader US biotech group at 2.5x.

The price to book ratio compares a company’s market value to its net assets on the balance sheet. For a clinical stage biotech like Spyre Therapeutics, where revenue is currently $0 and the company is loss making with net income of $150.213 million in the red, this metric often reflects how investors weigh the pipeline, management and trial progress against the accounting book value.

On a peer comparison, Spyre Therapeutics looks roughly in line with similar companies at 10.1x versus 10.6x. That suggests the market is assigning a comparable premium to its asset base relative to close peers. Against the wider US Biotechs industry though, the stock is priced at more than 4x the sector average of 2.5x. The market is therefore placing a much richer value on Spyre Therapeutics’ balance sheet than on the typical biotech, which implies investors are already baking in considerable optimism around its clinical programs and future optionality.

Result: Price-to-book of 10.1x (ABOUT RIGHT)

However, Spyre Therapeutics still faces key risks, including clinical trial setbacks in SPY772 or SKYLIGHT and potential equity dilution if funding needs increase.

Next Steps

If the mix of strong share price momentum and clinical risk around Spyre Therapeutics leaves you unsure, this is a good moment to review the data, stress test the downside and weigh up the 4 important warning signs.

Looking for more investment ideas beyond Spyre Therapeutics?

If Spyre Therapeutics is already on your radar, do not stop there. Broaden your opportunity set and give yourself more options before the next move in your portfolio.

• Target potential bargains that combine quality with attractive pricing by scanning 52 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies in the 12 dividend fortresses.
• Prioritise resilience by focusing on companies highlighted in the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.